AbbVie (ABBV) is expected to report a 23% surge in its fourth-quarter earnings, scheduled for February 4, before the opening bell.
The company’s EPS is seen coming in at $2.65, while revenue is projected to jump 8.7% to $16.41B.
In
AbbVie Q4 Preview: Here’s what to expect
